Does TECLISTAMAB-CQYV Cause Therapy cessation? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Therapy cessation have been filed in association with TECLISTAMAB-CQYV. This represents 0.8% of all adverse event reports for TECLISTAMAB-CQYV.
12
Reports of Therapy cessation with TECLISTAMAB-CQYV
0.8%
of all TECLISTAMAB-CQYV reports
1
Deaths
3
Hospitalizations
How Dangerous Is Therapy cessation From TECLISTAMAB-CQYV?
Of the 12 reports, 1 (8.3%) resulted in death, 3 (25.0%) required hospitalization.
Is Therapy cessation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TECLISTAMAB-CQYV. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does TECLISTAMAB-CQYV Cause?
Cytokine release syndrome (406)
Immune effector cell-associated neurotoxicity syndrome (153)
Off label use (122)
Death (116)
Plasma cell myeloma (96)
Infection (83)
Neutropenia (74)
Fatigue (72)
Pyrexia (67)
Covid-19 (64)
What Other Drugs Cause Therapy cessation?
DALFAMPRIDINE (4,580)
ETANERCEPT (2,031)
ADALIMUMAB (1,712)
ABIRATERONE (1,602)
VOXELOTOR (1,038)
CLOZAPINE (885)
LOMITAPIDE (828)
CAPECITABINE (746)
TREPROSTINIL (743)
ISOTRETINOIN (633)
Which TECLISTAMAB-CQYV Alternatives Have Lower Therapy cessation Risk?
TECLISTAMAB-CQYV vs TEDIZOLID
TECLISTAMAB-CQYV vs TEDUGLUTIDE
TECLISTAMAB-CQYV vs TEDUGLUTIDE\WATER
TECLISTAMAB-CQYV vs TEGAFUR
TECLISTAMAB-CQYV vs TEGAFUR\URACIL